ACOR - Acorda Therapeutics Inc Stock Price, Fair Value and News

0.52USD+0.06 (+13.04%)Market Closed

Market Summary

USD0.52+0.06

Market Closed

13.04%

ACOR Stock Price

View Fullscreen

ACOR RSI Chart

ACOR Valuation

Market Cap

645.9K

Price/Earnings (Trailing)

Price/Sales (Trailing)

0.01

EV/EBITDA

0.13

Price/Free Cashflow

-0.05

ACOR Price/Sales (Trailing)

ACOR Profitability

EBT Margin

-251.65%

Return on Equity

-160.08%

Return on Assets

-232.99%

Free Cashflow Yield

-2.2K%

ACOR Fundamentals

ACOR Revenue

Revenue (TTM)

117.6M

Rev. Growth (Yr)

20.7%

Rev. Growth (Qtr)

37.06%

ACOR Earnings

Earnings (TTM)

-252.9M

Earnings Growth (Yr)

-1.2K%

Earnings Growth (Qtr)

-2.4K%

Breaking Down ACOR Revenue

Last 30 days

-96.5%

Last 90 days

-97.4%

Trailing 12 Months

-95.4%

How does ACOR drawdown profile look like?

ACOR Financial Health

Current Ratio

0.33

ACOR Investor Care

Shares Dilution (1Y)

2.07%

Diluted EPS (TTM)

-203.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	118.3M	116.9M	111.1M	117.6M
2022	122.7M	122.0M	124.1M	118.6M
2021	153.7M	151.9M	130.3M	129.1M
2020	176.4M	159.9M	165.3M	153.0M
2019	409.4M	306.2M	211.1M	192.4M
2018	575.1M	588.9M	590.7M	471.4M
2017	523.1M	535.1M	540.5M	588.3M
2016	508.7M	522.5M	509.9M	519.6M
2015	420.8M	437.4M	479.6M	492.7M
2014	345.1M	355.2M	376.2M	401.5M
2013	306.4M	317.8M	325.3M	336.4M
2012	302.2M	312.6M	297.0M	305.8M
2011	235.1M	256.9M	286.3M	292.2M
2010	57.3M	86.0M	135.2M	191.1M
2009	0	53.8M	54.2M	54.7M
2008	0	0	0	53.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Acorda Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 17, 2023	cohen ron	bought	6,500	0.65	10,000	president and ceo
Mar 16, 2023	cohen ron	bought	6,093	0.6	10,156	president and ceo
Sep 03, 2022	clem kerry m	sold (taxes)	-601	0.398	-1,511	chief commercial officer
Sep 03, 2022	sabella lauren m	sold (taxes)	-601	0.398	-1,511	chief operating officer
Mar 17, 2022	cohen ron	sold	-3,894	1.7014	-2,289	president and ceo
Sep 03, 2021	morales robert	sold (taxes)	-1,962	4.38	-448	interim pao & pfo
Sep 03, 2021	sabella lauren m	sold (taxes)	-6,618	4.38	-1,511	chief commercial officer
Sep 03, 2021	cohen ron	sold (taxes)	-17,257	4.38	-3,940	president and ceo
Mar 03, 2021	blank burkhard	acquired	-	-	11,125	cmo and head of r&d
Mar 03, 2021	sabella lauren m	acquired	-	-	11,125	chief commercial officer

Which funds bought or sold ACOR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	0.69	2,190	163,093	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	Saltoro Capital, LP	unchanged	-	-146,250	731,250	1.95%
Feb 14, 2024	Davidson Kempner Capital Management LP	unchanged	-	51,285	801,257	0.02%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	754	754	-%
Feb 14, 2024	DEUTSCHE BANK AG\	sold off	-100	-25,483	-	-%
Feb 13, 2024	BlackRock Inc.	reduced	-2.21	-1,585	100,021	-%
Feb 13, 2024	ACADIAN ASSET MANAGEMENT LLC	unchanged	-	-	489,000	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	116	17,745	-%
Feb 13, 2024	FIRST MANHATTAN CO. LLC.	unchanged	-	1.00	45.00	-%

Are Funds Buying or Selling ACOR?

Are funds buying ACOR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACOR

No. of Funds

Unveiling Acorda Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 10, 2023	davidson kempner capital management lp	0.13%	31,311	SC 13D/A
Mar 10, 2023	davidson kempner capital management lp	0.21%	51,189	SC 13D/A
Feb 14, 2023	canyon capital advisors llc	0.00%	0	SC 13G/A
Feb 13, 2023	renaissance technologies llc	3.57%	868,892	SC 13G/A
Jan 23, 2023	davidson kempner capital management lp	0.24%	59,129	SC 13D/A
Jun 10, 2022	soros fund management llc	0%	0	SC 13G
Jun 10, 2022	davidson kempner capital management lp	0.28%	68,229	SC 13D
Feb 14, 2022	ubs oconnor llc	0%	0	SC 13G/A
Feb 14, 2022	point72 asset management, l.p.	4.1%	464,276	SC 13G/A
Feb 14, 2022	canyon capital advisors llc	5.79%	649,031	SC 13G/A

Recent SEC filings of Acorda Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 13, 2024	8-K	Current Report

Peers (Alternatives to Acorda Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	360.2B	85.2B	-3.67%	-8.64%	10.25	4.23	6.46%	95.94%
MRK	321.4B	60.1B	2.46%	9.45%	880.53	5.35	1.40%	-97.49%
PFE	148.6B	46.5B	-3.80%	-34.05%	-107.04	3.19	42.59%	-114.62%
AMGN	146.6B	28.2B	-0.95%	11.90%	21.82	5.2	7.09%	2.52%
GILD	83.5B	27.1B	-7.68%	-22.69%	14.74	3.08	-0.60%	23.36%
TEVA	14.6B	15.8B	-6.26%	55.93%	-25.32	0.92	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-2.65%	-15.52%	-325.34	0.89	4.58%	90.97%
ALKS	4.1B	1.7B	-11.07%	-16.83%	11.39	2.44	49.61%	324.78%
BHC	3.1B	8.8B	-10.77%	12.83%	-5.27	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.43%	-0.05%	14.31	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-20.35%	-21.70%	-4.05	1.92	24.65%	80.36%
TXMD	21.7M	1.3M	-17.90%	-49.19%	-2.11	16.65	-98.14%	-109.18%
ACRX	16.3M	-	-14.29%	38.83%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-32.73%	-94.43%	-0.18	0.13	80.00%	43.08%
ACOR	645.9K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Acorda Therapeutics Inc News

Latest updates

Acorda Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	37.1%	37,985,000	27,715,000	29,675,000	22,258,000	31,470,000	33,511,000	31,051,000	22,534,000	36,967,500	31,456,000	31,785,000	28,862,000	38,160,000	53,090,000	33,618,000	28,099,000	50,496,000	47,722,000	50,053,000	44,137,000	69,152,000
Costs and Expenses	843.7%	285,310,000	30,234,000	33,307,000	33,734,000	31,203,000	38,500,000	44,966,000	39,237,000	48,526,500	54,465,000	47,474,000	57,643,000	116,554,500	37,053,000	43,168,000	34,268,000	36,010,500	307,072,000	73,442,000	87,516,000	118,452,500
S&GA Expenses	-4.1%	22,206,500	23,152,000	21,825,000	22,514,000	26,254,000	22,997,000	30,067,000	26,938,000	28,440,000	29,623,000	32,368,000	33,968,000	32,876,500	39,935,000	38,656,000	41,108,000	41,224,000	48,702,000	50,195,000	52,725,000	36,819,000
R&D Expenses	-16.4%	1,009,000	1,207,000	1,550,000	1,386,000	1,202,000	1,383,000	1,525,000	1,694,000	1,366,000	1,931,000	2,374,000	4,749,000	4,323,000	5,729,000	5,255,000	7,705,000	9,023,000	16,073,000	18,959,000	16,028,000	27,058,000
EBITDA Margin	-597.2%	-1.98	0.40	0.35	0.28	0.23	-0.10	-0.25	-0.27	-0.35	-0.84	-0.45	-	-	-	-	-	-	-	-	-	-
Interest Expenses	2.8%	8,205,000	7,984,000	7,773,000	7,571,000	7,699,000	7,465,000	7,474,000	7,562,000	7,338,000	7,167,000	7,705,000	7,825,000	7,764,000	7,760,000	7,484,000	7,566,000	5,570,000	4,500,000	5,378,000	6,424,000	5,271,000
Income Taxes	-3362.5%	-38,088,000	-1,100,000	-2,000,000	-2,000,000	2,419,000	1,400,000	26,600,000	300,000	1,680,000	-3,100,000	-500,000	-3,200,000	-3,092,000	1,465,000	571,000	-6,998,000	-791,500	20,000	214,000	-715,000	-63,081,500
Earnings Before Taxes	-2473.4%	-255,870,000	-9,943,000	-11,346,000	-18,862,000	21,574,000	-12,438,000	-20,119,000	-24,264,000	-18,899,500	-30,176,000	-23,395,000	-36,603,000	-86,159,000	8,812,000	-16,850,000	-13,470,000	64,862,000	-263,518,000	-27,272,000	-48,320,000	-53,465,500
EBT Margin	-1405.2%	-2.52	-0.17	-0.18	-0.25	-0.30	-0.61	-0.77	-0.79	-0.85	-1.35	-0.90	-	-	-	-	-	-	-	-	-	-
Net Income	-2350.1%	-217,761,000	-8,888,000	-9,381,000	-16,824,000	19,142,000	-13,854,000	-46,682,000	-24,522,000	-20,567,500	-27,071,000	-22,864,000	-33,451,000	-83,048,000	7,347,000	-17,421,000	-6,472,000	65,660,000	-263,535,000	-27,486,000	-47,605,000	9,595,000
Net Income Margin	-1397.4%	-2.15	-0.14	-0.18	-0.49	-0.56	-0.85	-0.97	-0.77	-0.81	-1.28	-0.87	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-140.2%	-3,062,000	7,608,000	-11,556,000	-7,018,000	9,066,000	-1,866,000	-14,584,000	-13,676,000	3,239,000	-9,012,000	-8,824,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-70.4%	109	366	365	375	396	393	406	424	455	466	491	584	633	710	728	754	800	880	1,197	1,234	1,300
Current Assets	1.4%	75.00	74.00	65.00	68.00	82.00	72.00	77.00	80.00	102	97.00	113	190	221	152	158	168	201	314	358	418	528
Cash Equivalents	-7.7%	30.00	32.00	25.00	30.00	38.00	21.00	23.00	32.00	46.00	36.00	46.00	117	71.00	58.00	41.00	32.00	62.00	120	148	197	294
Inventory	-10.0%	16.00	18.00	15.00	13.00	13.00	15.00	15.00	15.00	19.00	21.00	25.00	27.00	29.00	30.00	33.00	26.00	25.00	27.00	28.00	31.00	29.00
Net PPE	-5.9%	2.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	5.00	6.00	6.00	7.00	139	142	143	143	131	113	83.00	61.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	281	280	282
Current Liabilities	392.0%	228	46.00	30.00	35.00	38.00	42.00	41.00	46.00	54.00	68.00	68.00	133	137	139	138	71.00	86.00	92.00	94.00	97.00	140
Long Term Debt	-100.0%	-	181	176	171	167	163	159	155	151	147	144	141	138	135	132	195	193	326	324	321	319
LT Debt, Non Current	-100.0%	-	181	176	171	167	163	159	155	151	147	144	141	138	135	132	195	193	326	324	321	319
Shareholder's Equity	167.9%	158	59.00	68.00	77.00	94.00	76.00	88.00	128	151	164	190	206	238	314	291	307	311	281	545	567	612
Retained Earnings	-22.4%	-1,189	-971	-962	-953	-936	-955	-941	-894	-870	-849	-822	-799	-766	-683	-690	-673	-666	-732	-468	-441	-393
Additional Paid-In Capital	0.0%	1,030	1,030	1,030	1,030	1,030	1,030	1,029	1,024	1,023	1,016	1,016	1,008	1,008	1,000	983	981	979	1,015	1,012	1,009	1,005
Shares Outstanding	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	16.00	-	-	-	11.00	-	-	-	52.00	-	-	-	35.00	-	-	-	363	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-139.7%	-3,018	7,608	-11,556	-7,018	9,066	-1,839	-14,514	-13,637	3,240	-9,012	-8,688	-26,888	1,448	-2,905	-20,770	-38,779	-11,429	-24,351	-14,891	-77,496	-12,338
Share Based Compensation	-2.1%	138	141	128	71.00	173	364	471	485	480	854	954	707	1,588	2,480	2,056	1,976	2,756	3,293	4,534	3,667	5,006
Cashflow From Investing	-Infinity%	-44.00	-	-	-	123	-150	-70.00	-39.00	-1.00	-	-136	73,915	5,019	20,148	23,150	11,043	55,998	-3,276	-35,106	-18,121	-14,829
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-	-69,000	-655	-	-90.00	-	-1,578	-59,869	-	-39.00	-642	62.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.00	52.00	157

ACOR Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total net revenues	$ 117,633	$ 118,566
Costs and expenses:
Cost of sales	15,283	30,332
Research and development	5,152	5,804
Selling, general and administrative	89,698	106,256
Intangible asset impairment	251,322
Amortization of intangible assets	30,764	30,764
Changes in fair value of derivative liability		(37)
Changes in fair value of acquired contingent consideration	(9,634)	(6,659)
Other operating income		(12,554)
Total operating expenses	382,585	153,906
Operating loss	(264,952)	(35,340)
Other income (expense), net:
Interest and amortization of debt discount expense	(31,533)	(30,200)
Interest income	530	1,909
Realized Gain (Loss) on FX Currency	(288)	(8)
Gain on extinguishment of debt		27,142
Gain on disposal of property and equipment	171
Other income (expense)	51	1,250
Total other income (expense), net	(31,069)	93
Loss before taxes	(296,021)	(35,247)
Benefit from (Provision for) income taxes	43,167	(30,669)
Net loss	$ (252,854)	$ (65,916)
Net loss per share—basic	$ (203.57)	$ (65.23)
Net loss per share—diluted	$ (203.57)	$ (65.23)
Weighted average common shares outstanding used in computing net loss per share—basic	1,242	1,011
Weighted average common shares outstanding used in computing net loss per share—diluted	1,242	1,011
Net Product Revenues
Revenues:
Total net revenues	$ 102,421	$ 103,845
Royalty Revenues
Revenues:
Total net revenues	15,113	14,221
License Revenue
Revenues:
Total net revenues	$ 99	$ 500

ACOR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 29,979	$ 37,536
Restricted cash	381	6,884
Trade accounts receivable, net of allowances of $962 and $842, as of December 31, 2023 and 2022, respectively	17,298	13,866
Prepaid expenses	5,211	4,312
Inventory, net	16,155	12,752
Other current assets	5,770	6,765
Total current assets	74,794	82,115
Property and equipment, net of accumulated depreciation	2,079	2,603
Intangible assets, net of accumulated amortization and impairment	22,987	305,087
Right of use asset, net of accumulated amortization	4,221	5,287
Restricted cash	255	255
Other assets	4,189	248
Total assets	108,525	395,595
Current liabilities:
Accounts payable	13,373	9,809
Accrued expenses and other current liabilities	24,310	23,680
Convertible senior notes	186,143	0
Current portion of lease liability	1,588	1,545
Current portion of acquired contingent consideration	2,132	2,532
Deferred revenue	227	384
Total current liabilities	227,773	37,950
Convertible senior notes	0	167,031
Non-current portion of acquired contingent consideration	27,368	38,668
Deferred tax liability	0	44,202
Non-current portion of lease liability	3,166	4,341
Other non-current liabilities	8,174	9,781
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at December 31, 2023 and 2022; no shares issued as of December 31, 2023 and 2022
Common stock, $0.001 par value per share. Authorized 3,083,333 shares at December 31, 2023 and 2022; issued 1,242,376 and 1,242,376 shares, including those held in treasury, as of December 31, 2023 and 2022, respectively	1	24
Treasury stock at cost (278 shares at December 31, 2023 and December 31, 2022)	(638)	(638)
Additional paid-in capital	1,030,383	1,029,881
Accumulated deficit	(1,189,127)	(936,273)
Accumulated other comprehensive loss	1,425	628
Total stockholders' equity (deficit)	(157,956)	93,622
Total liabilities and stockholders’ equity	$ 108,525	$ 395,595

About Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

CEO	Dr. Ron Cohen M.D.
WEBSITE	acorda.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	111

Acorda Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Acorda Therapeutics Inc? What does ACOR stand for in stocks?

ACOR is the stock ticker symbol of Acorda Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acorda Therapeutics Inc (ACOR)?

As of Tue Apr 23 2024, market cap of Acorda Therapeutics Inc is 645.89 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACOR stock?

You can check ACOR's fair value in chart for subscribers.

What is the fair value of ACOR stock?

You can check ACOR's fair value in chart for subscribers. The fair value of Acorda Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acorda Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACOR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acorda Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACOR is over valued or under valued. Whether Acorda Therapeutics Inc is cheap or expensive depends on the assumptions which impact Acorda Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACOR.

What is Acorda Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, ACOR's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACOR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Acorda Therapeutics Inc's stock?

In the past 10 years, Acorda Therapeutics Inc has provided -0.601 (multiply by 100 for percentage) rate of return.